Evotec SE has expanded its strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Key achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology, triggering a program-based payment of $50 million to Evotec.    The companies entered their strategic protein degradation partnership in 2018 and expanded it in May of 2022, based on the highly productive initial collaboration generating a promising pipeline. S...